Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01234402 |
|
Recruitment Status :
Completed
First Posted : November 4, 2010
Results First Posted : August 14, 2019
Last Update Posted : August 14, 2019
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
An open-label, multicenter, randomized, Phase 2 trial in which participant with unresectable, locally advanced or metastatic breast cancer who have been previously treated with anthracycline and taxane therapy receive ramucirumab DP or Icrucumab (IMC-18F1) administered on an every-21-day cycle (in combination with oral capecitabine therapy; capecitabine is administered twice a day on Days 1-14 of each cycle). Approximately 150 participants will be randomized in a 1:1:1 ratio to either ramucirumab DP or Icrucumab (IMC-18F1) in combination with capecitabine (Arm A and Arm B, respectively) or capecitabine monotherapy (Arm C). Randomization will be stratified by triple-negative receptor status (estrogen receptor-negative, progesterone receptor-negative, and human epidermal growth factor receptor-2 [HER2/neu]-negative) (yes/no) and receipt of prior antiangiogenic therapy.
Treatment with the study medication(s) will continue until disease progression, the development of unacceptable toxicity, noncompliance or withdrawal of consent by the participant, or investigator decision. Capecitabine dose reductions in the setting of significant myelosuppression, hand-and-foot syndrome, or diarrhea will be required.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Breast Cancer | Biological: Ramucirumab DP Biological: IMC-18F1 Drug: Capecitabine | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 153 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirumab (IMC-1121B) Drug Product or Icrucumab (IMC-18F1) in Combination With Capecitabine or Capecitabine Monotherapy, in Unresectable, Locally Advanced or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy |
| Study Start Date : | March 2011 |
| Actual Primary Completion Date : | October 2013 |
| Actual Study Completion Date : | July 2017 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Ramucirumab DP + Capecitabine
Cycles repeat until disease progression, the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant.
|
Biological: Ramucirumab DP
10 mg/kg I.V. Day 1 of every-21-day cycle Other Names:
Drug: Capecitabine 1000 mg/m^2 orally Twice a day for 14 days |
|
Experimental: Icrucumab + Capecitabine
Cycles repeat until disease progression, the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant.
|
Biological: IMC-18F1
12 mg/kg I.V. Days 1 and 8 of every-21-day cycle Other Names:
Drug: Capecitabine 1000 mg/m^2 orally Twice a day for 14 days |
|
Active Comparator: Capecitabine*
Crossover Study: * At the discretion of the investigator, participants will be eligible to receive either ramucirumab DP or Icrucumab (IMC-18F1) in combination with capecitabine, after radiographic disease progression while on capecitabine. The investigator will decide which investigational product will be given. Cycles repeat every 21 days until disease progression, the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant. |
Drug: Capecitabine
1000 mg/m^2 orally Twice a day for 14 days |
- Progression-Free Survival (PFS) [ Time Frame: From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 97 weeks) ]PFS is defined as the time from the date of randomization until the date of objectively determined progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) or death from any cause, whichever is first. Disease progression is defined as ≥20% increase in the sum of diameters of target lesions, taking as reference smallest sum on study (included baseline sum if that was the smallest on study); sum must have demonstrated an absolute increase of ≥5 millimeter (mm) and the appearance of ≥1 new lesions was progression. Participants who did not progress, were lost to follow-up, or had missed 2 or more scheduled tumor assessments were censored at the day of their last adequate tumor assessment.
- Overall Survival (OS) [ Time Frame: From Date of Randomization until Death Due to Any Cause (Up To 160 weeks) ]Overall survival is defined as the time from the date of randomization to the date of death from any cause. If the participant is alive at the end of the follow-up period or is lost to follow-up, OS will be censored on the last date the participant is known to be alive.
- Percentage of Participants With Objective Response Rate (ORR) [ Time Frame: From Date of Randomization until Disease Progression/Recurrence (Up to 97 weeks) ]The ORR is the number of all participants with Partial Response (PR) or Complete Response (CR) according to RECIST v1.1 from the start of the treatment until disease progression/recurrence. CR was defined as the disappearance of all non-nodal target lesions, with the short axes of any target lymph nodes reduced to <10 mm. PR was defined as ≥30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph nodes), taking as reference the baseline sum diameter. Disease progression is defined as ≥20% increase in the sum of diameters of target lesions, taking as reference smallest sum on study (included baseline sum if that was the smallest on study); sum must have demonstrated an absolute increase of ≥5 mm and the appearance of ≥1 new lesions was progression.
- Duration of Response [ Time Frame: From Date of CR, PR until Disease Progression or Death Due to Any Cause (Up To 97 weeks) ]Duration of response is measured from the time measurement criteria are first met for CR/PR (whichever is first recorded) until the first date that the criteria for progressive disease (PD) is met (taking as a reference for PD that smallest measurement recorded since the treatment started), or death, is objectively documented.CR was defined as the disappearance of all non-nodal target lesions, with the short axes of any target lymph nodes reduced to <10 mm. PR was defined as ≥30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph nodes), taking as reference the baseline sum diameter.PD defined as ≥20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). Sum must also have demonstrated an absolute increase of ≥5 mm, or the appearance of 1 or more new lesions was considered progression.
- Number of Participants With Adverse Events (AEs) [ Time Frame: Up To 160 Weeks ]
Adverse event (AE) will be regarded as treatment-emergent if onset date occurs any time on or after the administration of the first dose of study treatment up to 30 days after the last dose of study treatment (or up to any time if related to study treatment); or it occurs prior to first dose date and worsens while on therapy or up to 30 days after the last dose of study treatment (or up to any time if related to study treatment).
A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.
- Number of Participants With Serious Adverse Events (SAEs) [ Time Frame: Up To 160 Weeks ]
SAE was defined as any untoward medical occurrence that at any dose:
Resulted in death; Was life-threatening; Required inpatient hospitalization or caused prolongation of existing hospitalization; Resulted in persistent or significant disability/incapacity; Was a congenital anomaly/birth defect; Required intervention to prevent permanent impairment/damage; Was an important medical event (defined as a medical event that may not have been immediately life-threatening or resulted in death or hospitalization but, based upon appropriate medical and scientific judgment, may jeopardize the participant or may require intervention to prevent one of the other serious outcomes listed in the definition above).
A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.
- Maximum Concentration (Cmax) Ramucirumab Drug Product (DP) or Icrucumab [ Time Frame: Cycle 1: Pre-infusion, 1h, 48h, 72h, 168, 336h post infusion ]
- Minimum Concentration (Cmin) Ramucirumab Drug Product (DP) or Icrucumab [ Time Frame: Cycle 2,4,6,8,0,12,14,16,18,22: Pre-infusion, 1h, 48h, 72h, 168, 336h post infusion ]Minimum Concentration (Cmin) Ramucirumab Drug Product (DP) or Icrucumab.
- Area Under the Concentration Versus Time Curve From Time Zero to Infinity of Ramucirumab or Icrucumab [ Time Frame: Cycle 1: Pre-infusion, 1h, 48h, 72h, 168, 336h post infusion ]Area Under the Concentration (AUC) Versus Time Curve From Time Zero to Infinity of Ramucirumab and Icrucumab.
- Terminal Half-life (t½) of Ramucirumab or Icrucumab [ Time Frame: Cycle 1: Pre-infusion, 1h, 48h, 72h, 168, 336h post infusion ]Terminal half-life (t½) of Ramucirumab and Icrucumab.
- Clearance (Cl) of Ramucirumab or Icrucumab [ Time Frame: Cycle 1: Pre-infusion, 1h, 48h, 72h, 168, 336h post infusion ]Clearance (Cl) of Ramucirumab and Icrucumab.
- Volume of Distribution at Steady State (Vss) of Ramucirumab or Icrucumab [ Time Frame: Cycle 1: Pre-infusion, 1h, 48h, 72h, 168, 336h post infusion ]Volume of Distribution at Steady State (Vss) of Ramucirumab and Icrucumab.
- Number of Participants With Anti-Ramucirumab and Anti-Icrucumab Antibodies [ Time Frame: Cycle 1: Pre-infusion, 1h, 48h, 72h, 168, 336h post infusion ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- The participant has histologically or cytologically confirmed breast cancer which at the time of study entry is either Stage III disease not amenable to curative therapy or Stage IV disease
- Has measurable or nonmeasurable disease
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Has received prior anthracycline therapy
- Has received prior taxane therapy
- Participants with human epidermal growth factor receptor-2 (HER2) positive disease must have progressed on or following trastuzumab
- Participants with hormone receptor-positive disease must have progressed on or following hormone therapy
- Has received ≤ 3 prior chemotherapy regimens in any setting (a regimen is defined as any agent[s] that has been administered for more than 1 cycle; sequential neoadjuvant/adjuvant treatment is considered 1 regimen)
- Has completed any prior radiotherapy ≥ 4 weeks prior to randomization
- Has completed any prior hormonal therapy ≥ 2 weeks prior to randomization
- Has adverse events (AEs) that have resolved to Grade ≤ 1 by the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI-CTCAE v 4.0) from all clinically significant toxic effects of prior chemotherapy, surgery, radiotherapy,or hormonal therapy
- Has adequate hematologic, coagulation, hepatic and renal function
-
Does not have:
- cirrhosis at a level of Child-Pugh B (or worse) or
- cirrhosis (any degree) and a history of hepatic encephalopathy or ascites resulting from cirrhosis and requiring ongoing treatment with diuretics and/or paracentesis
- Has urinary protein is ≤ 1+ on dipstick or routine urinalysis; if urine protein ≥ 2+, a 24-hour urine collection must demonstrate < 1000 mg of protein in 24 hours to allow participation in the study
- Agrees to use adequate contraception during the study period and for 12 weeks after the last dose of study medication
Exclusion Criteria:
- Has a concurrent active malignancy other than adequately treated nonmelanomatous skin cancer, curatively treated cervical carcinoma in situ, or other noninvasive carcinoma or in situ neoplasm. A participant with previous history of malignancy is eligible, provided that there has been a disease-free interval for > 3 years
- Has a known sensitivity to capecitabine, any of its components, or other drugs formulated with polysorbate 80
- Has a known sensitivity to 5-fluorouracil (5-FU)
- Has a known dihydropyrimidine dehydrogenase deficiency
- Has received prior capecitabine treatment for advanced breast cancer
- Has received investigational therapy within 2 weeks prior to randomization
- Has received bevacizumab within 4 weeks prior to randomization
- Has received more than 1 prior antiangiogenic agent for breast cancer
- Has a known sensitivity to agents of similar biologic composition as ramucirumab DP or Icrucumab (IMC-18F1), or other agents that specifically target vascular endothelial growth factor (VEGF)
- Has an acute/subacute bowel obstruction or history of chronic diarrhea requiring ongoing medical intervention
- Has a history of uncontrolled hereditary or acquired bleeding or thrombotic disorders
- Has experienced a Grade ≥ 3 bleeding event within 3 months prior to randomization
- Is receiving prophylactic or therapeutic anticoagulation with warfarin or any other oral anticoagulant
- Has an uncontrolled intercurrent illness, including, but not limited to uncontrolled hypertension, symptomatic anemia, symptomatic congestive heart failure, unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia, psychiatric illness/social situations, or any other serious uncontrolled medical disorder in the opinion of the investigator
- Has experienced any arterial thrombotic or thromboembolic events, including, but not limited to myocardial infarction, transient ischemic attack, or cerebrovascular accident within 6 months prior to randomization
- Has brain metastases, uncontrolled spinal cord compression, or leptomeningeal disease
- Has an ongoing or active infection requiring parenteral antibiotic, antifungal, or antiviral therapy
- Has received a prior allogeneic organ or tissue transplantation
- Has undergone major surgery within 4 weeks prior to randomization, or subcutaneous venous access device placement within 7 days prior to randomization
- Has had a serious nonhealing wound, ulcer, or bone fracture within 4 weeks prior to randomization
- Has known HIV or AIDS infection
- Has an elective or planned major surgery to be performed during the course of the trial
- Participant is pregnant or lactating
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01234402
| United States, Arizona | |
| ImClone Investigational Site | |
| Scottsdale, Arizona, United States, 85259 | |
| United States, California | |
| ImClone Investigational Site | |
| Los Angeles, California, United States, 90033 | |
| United States, Florida | |
| ImClone Investigational Site | |
| Jacksonville, Florida, United States, 32224 | |
| United States, Georgia | |
| ImClone Investigational Site | |
| Atlanta, Georgia, United States, 30322 | |
| ImClone Investigational Site | |
| Augusta, Georgia, United States, 30912 | |
| United States, Illinois | |
| ImClone Investigational Site | |
| Chicago, Illinois, United States, 60611 | |
| United States, Indiana | |
| ImClone Investigational Site | |
| Indianapolis, Indiana, United States, 46202 | |
| United States, Louisiana | |
| ImClone Investigational Site | |
| Baton Rouge, Louisiana, United States, 70809 | |
| United States, New York | |
| ImClone Investigational Site | |
| Bronx, New York, United States, 10461 | |
| ImClone Investigational Site | |
| New York, New York, United States, 10021 | |
| ImClone Investigational Site | |
| Stony Brook, New York, United States, 11794 | |
| United States, North Carolina | |
| ImClone Investigational Site | |
| Washington, North Carolina, United States, 27889 | |
| United States, Ohio | |
| ImClone Investigational Site | |
| Cincinnati, Ohio, United States, 45242 | |
| ImClone Investigational Site | |
| Columbus, Ohio, United States, 43219 | |
| United States, Texas | |
| ImClone Investigational Site | |
| Dallas, Texas, United States, 75390 | |
| ImClone Investigational Site | |
| San Antonio, Texas, United States, 78229 | |
| United States, Utah | |
| ImClone Investigational Site | |
| Salt Lake City, Utah, United States, 84106 | |
| United States, Virginia | |
| ImClone Investigational Site | |
| Richmond, Virginia, United States, 23230 | |
| United States, Washington | |
| ImClone Investigational Site | |
| Spokane, Washington, United States, 99208 | |
| United States, West Virginia | |
| ImClone Investigational Site | |
| Morgantown, West Virginia, United States, 26506 | |
| Canada, Alberta | |
| ImClone Investigational Site | |
| Calgary, Alberta, Canada, T2N 4N2 | |
| ImClone Investigational Site | |
| Edmonton, Alberta, Canada, T6G 1Z2 | |
| Canada, Ontario | |
| ImClone Investigational Site | |
| Toronto, Ontario, Canada, M4N 3M5 | |
| Study Director: | Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) | Eli Lilly and Company |
| Responsible Party: | Eli Lilly and Company |
| ClinicalTrials.gov Identifier: | NCT01234402 |
| Other Study ID Numbers: |
13944 CP20-0903 ( Other Identifier: ImClone LLC ) I4Y-IE-JCDD ( Other Identifier: Eli Lilly and Company ) |
| First Posted: | November 4, 2010 Key Record Dates |
| Results First Posted: | August 14, 2019 |
| Last Update Posted: | August 14, 2019 |
| Last Verified: | July 2019 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com. This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement. |
|
Breast Cancer |
|
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Capecitabine Ramucirumab Antimetabolites, Antineoplastic |
Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Growth Inhibitors |